FOLFOX4化疗方案联合得力生治疗晚期胃癌的临床研究  

The clinical efficacy of FOLFOX4 chemotherapy combined with Delisheng in therapy of advanced gastic cancer

作　　者：何肇晴[1] 程冬英[1] 龚皓[1] 程杰[1] 徐朱俊[1] 陈丹[1] 李婧[1] 汪锐[1] 

机构地区：[1]武汉市第一医院肿瘤中心,湖北武汉430022

出　　处：《现代肿瘤医学》2008年第3期408-411,共4页Journal of Modern Oncology

摘　　要：目的:通过前瞻性研究与单纯性FOLFOX4方案对照比较,观察FOLFOX4方案联合得力生注射液治疗晚期胃癌的临床疗效。方法:将123例中晚期胃癌住院患者随机分为单纯性FOLFOX4方案对照组和得力生加FOLFOX4方案实验组,分别给予相应治疗,观察两组近期临床疗效、生活质量、免疫指标、毒副作用等。结果:FOLFOX4联合得力生注射液治疗晚期胃癌疗效确切,其血液学毒性反应、胃肠反应、神经毒性以及脱发等副作用均显著低于单纯性FOLFOX4方案对照组,患者的生活质量明显改善,治疗耐受能力增强。结论:FOLFOX4化疗方案联合得力生注射液治疗晚期胃癌,能够改善患者生活质量,降低化疗期间的毒副作用,提高免疫力,可使患者病情进展延缓。Objective： to explore the clinical efficacy of FOLFOX4 combined with Delisheng in lhe therapy of advanced gastic cancer. Methods： Total of 123 cases of gastric cancer patients 65 eases in Ihe Iherapy group treated by FOLFOX4 and Delisheng, the control group 58 patients treated by FOLFOX4. Results： In the therapy group, the toxic reaction of hematology, gastrointestinal reaction, neurotoxicity and defluvium were significantly lower than the control group, the life quality and compliance of the therapy group were better than the control group. Conclusion： FOLFOX4 combined with Delisheng in the therapy of advanced gastric cancer can notably improve life quality, degrade the side effects of chemotherapy, enhance the immunity of patients.

关 键 词：晚期胃癌 得力生 FOLFOX4 毒副作用 

分 类 号：R735.2[医药卫生—肿瘤]